Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells

Food and Chemical Toxicology

Volumn 60, Issue , 2013, Pages 360-368

  Cufí, Sílvia ^a,b   Bonavia, Rosa ^c   Vazquez Martin, Alejandro ^a,b   Corominas Faja, Bruna ^a,b   Oliveras Ferraros, Cristina ^a,b   Cuyàs, Elisabet ^a,b   Martin Castillo, Begoña ^a,b   Barrajón Catalán, Enrique ^d,e   Visa, Joana ^a   Segura Carretero, Antonio ^g   Bosch Barrera, Joaquim ^a,b   Joven, Jorge ^f   Micol, Vicente ^d,e   Menendez, Javier A ^a,b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^c BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^d MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^e MONTELOEDER S L   (Spain)

^f UNIVERSITY OF GRANADA   (Spain)

^g INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

Author keywords

EMT; Gefitinib; Lung cancer; Milk thistle; Silibinin; Silibinin meglumine

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; ISOSILYBIN A; ISOSILYBIN B; SILIBININ MEGLUMINE; SILIDIANIN; SILYBIN A; SILYBIN B; SILYBUM MARIANUM EXTRACT; SILYCHRISTIN A; SILYCHRISTIN B; UNCLASSIFIED DRUG; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; DRUG ISOLATION; DRUG SOLUBILITY; EPITHELIAL MESENCHYMAL TRANSITION; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN SYNTHESIS; TUMOR VOLUME;

EMT; GEFITINIB; LUNG CANCER; MILK THISTLE; SILIBININ; SILIBININ MEGLUMINE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MEGLUMINE; MICE; MICE, INBRED NOD; MILK THISTLE; PLANT EXTRACTS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEEDS; SILYMARIN; TANDEM MASS SPECTROMETRY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84883144344     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.07.063     Document Type: Article

References (59)

1. Brinda B.J., Zhu H.J., Markowitz J.S. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2012, 902:1-9.
2. Bryant J.L., Britson J., Balko J.M., Willian M., Timmons R., Frolov A., Black E.P. A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br. J. Cancer 2012, 106:148-156.
3. Byers L.A., Diao L., Wang J., Saintigny P., Girard L., Peyton M., Shen L., Fan Y., Giri U., Tumula P.K., Nilsson M.B., Gudikote J., Tran H., Cardnell R.J., Bearss D.J., Warner S.L., Foulks J.M., Kanner S.B., Gandhi V., Krett N., Rosen S.T., Kim E.S., Herbst R.S., Blumenschein G.R., Lee J.J., Lippman S.M., Ang K.K., Mills G.B., Hong W.K., Weinstein J.N., Wistuba I.I., Coombes K.R., Minna J.D., Heymach J.V. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin. Cancer Res. 2013, 19:279-290.
4. Calani L., Brighenti F., Bruni R., Del Rio D. Absorption and metabolism of milk thistle flavanolignans in humans. Phytomedicine 2012, 20:40-46.
5. Cao X., Deng W.W., Fu M., Wang L., Tong S.S., Wei Y.W., Xu Y., Su W.Y., Xu X.M., Yu J.N. In vitro release and in vitro-in vivo correlation for silybin meglumine incorporated into hollow-type mesoporous silica nanoparticles. Int. J. Nanomedicine 2012, 7:753-762.
6. Chang T.H., Tsai M.F., Su K.Y., Wu S.G., Huang C.P., Yu S.L., Yu Y.L., Lan C.C., Yang C.H., Lin S.B., Wu C.P., Shih J.Y., Yang P.C. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am. J. Respir. Crit. Care Med. 2011, 183:1071-1079.
7. Chen P.N., Hsieh Y.S., Chiou H.L., Chu S.C. Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways. Chem. Biol. Interact. 2005, 156:141-150.
8. Chinese-State-Drug-Administration, 2002. The Medical Hepatobiliary Fascicule of Chinese Patent Medicine from Local Standard to National Standard. In: C.S.D. Administration. Chinese State Drug Standard. pp. 299-303.
9. Cho H.J., Suh D.S., Moon S.H., Song Y.J., Yoon M.S., Park D.Y., Choi K.U., Kim Y.K., Kim K.H. Silibinin Inhibits Tumor Growth through Downregulation of Extracellular Signal-Regulated Kinase and Akt in Vitro and in Vivo in Human Ovarian Cancer Cells. J. Agric. Food Chem. 2013, 2013. April 18. [Epub ahead of print].
10. Chu S.C., Chiou H.L., Chen P.N., Yang S.F., Hsieh Y.S. Silibinin inhibits the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Mol. Carcinog. 2004, 40:143-149.
11. Chung J.H., Rho J.K., Xu X., Lee J.S., Yoon H.I., Lee C.T., Choi Y.J., Kim H.R., Kim C.H., Lee J.C. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer 2011, 73:176-182.
12. Coldren C.D., Helfrich B.A., Witta S.E., Sugita M., Lapadat R., Zeng C., Barón A., Franklin W.A., Hirsch F.R., Geraci M.W., Bunn P.A. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol. Cancer Res. 2006, 4:521-528.
13. Dave B., Mittal V., Tan N.M., Chang J.C. Epithelial-mesenchymal transition, cancer stem cells and treatment resistance. Breast Cancer Res. 2012, 14:202.
14. De Craene B., Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 2013, 13:97-110.
15. de Groot H., Rauen U. Tissue injury by reactive oxygen species and the protective effects of flavonoids. Fundam. Clin. Pharmacol. 1998, 12:249-255.
16. Deep G., Gangar S.C., Agarwal C., Agarwal R. Role of E-cadherin in antimigratory and antiinvasive efficacy of silibinin in prostate cancer cells. Cancer Prev. Res. (Phila) 2011, 4:1222-1232.
17. Flora K., Hahn M., Rosen H., Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 1998, 93:139-143.
18. Fraschini F., Demartini G., Esposti D. Pharmacology of silymarin. Clin. Drug Invest. 2002, 22:51-65.
19. Fuchs B.C., Fujii T., Dorfman J.D., Goodwin J.M., Zhu A.X., Lanuti M., Tanabe K.K. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 2008, 68:2391-2399.
20. Halbach G., Trost W. Chemistry and pharmacology of silymarin. Studies on various metabolites of silybin. Arzneimittelforschung 1974, 24:866-867.
21. He J., Hou S.X., Feng J.F., Cai B.Q. Effect of particle size on oral absorption of silymarin-loaded solid lipid nanoparticles. Zhongguo Zhong Yao Za Zhi 2005, 30:1651-1653.
22. Hui L., Zhang S., Dong X., Tian D., Cui Z., Qiu X. Prognostic significance of twist and N-cadherin expression in NSCLC. PLoS One 2013, 8:e62171.
23. Javed S., Kohli K., Ali M. Reassessing bioavailability of silymarin. Altern. Med. Rev. 2011, 16:239-249.
24. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119:1420-1428.
25. Kidd P.M. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern. Med. Rev. 2009, 14:226-246.
26. Kuki A., Nagy L., Deák G., Nagy M., Zsuga M., Kéki S. Identification of silymarin constituents: an improved HPLC-MS method. Chromatographia 2012, 75:175-180.
27. Lee D.Y., Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, Isolated from Silybum marianum (milk thistle). J. Nat. Prod. 2003, 66:1171-1174.
28. Liu F.Z., Yan K.X. Study on the beta-CB silymarin. Lishizhen Medicine and Materia Medica Res. 1996, 7:146-147.
29. Lu Y.K., JIi S.Y., Zhong L. Effect of silybin-MG on the production of nitric oxide in rat renal tissue induced by cisplatin. J. Dalian Med. Univ. 1999, 61:7-10.
30. Mateen S., Raina K., Agarwal C., Agarwal R. Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small-cell lung cancer cells. Epigenetics 2012, 10:1161-1172.
31. Mateen S., Raina K., Agarwal C., Chan D., Agarwal R. Silibinin synergizes with histone deacetylase and DNA methyltransferase inhibitors in upregulating e-cadherin expression together with inhibition of migration and invasion of human non-small cell lung cancer cells. J. Pharmacol. Exp. Ther. 2013, 345:206-214.
32. Mateen S., Tyagi A., Agarwal C., Singh R.P., Agarwal R. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol. Carcinogenesis 2010, 49:247-258.
33. Meng F., Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev. 2012, 31:455-467.
34. Micalizzi D.S., Farabaugh S.M., Ford H.L. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia 2010, 15:117-134.
35. Morazzoni P., Montalbetti A., Malandrino S., Pifferi G. Comparative pharmacokinetics of silipide and silymarin in rats. Eur. J. Drug Metab. Pharmacokinet. 1993, 18:289-297.
36. Nakashima H., Hashimoto N., Aoyama D., Kohnoh T., Sakamoto K., Kusunose M., Imaizumi K., Takeyama Y., Sato M., Kawabe T., Hasegawa Y. Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells. Mol. Carcinog. 2012, 51:400-410.
37. Nieto M.A., Cano A. The epithelial-mesenchymal transition under control: global programs to regulate epithelial plasticity. Sem. Cancer Biol. 2012, 22:361-368.
38. Nurwidya F., Takahashi F., Murakami A., Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res. Treat. 2012, 44:151-156.
39. Pallier K., Cessot A., CÔté J.F., Just P.A., Cazes A., Fabre E., Danel C., Riquet M., Devouassoux-Shisheboran M., Ansieau S., Puisieux A., Laurent-Puig P., Blons H. TWIST1 a new determinant of epithelial to mesenchymal transition in EGFR mutated lung adenocarcinoma. PLoS One 2012, 7:e29954.
40. Pei W., Chen Y.-p., Li J. Progress in research and application of silymarin. Med. Aromat. Plant Sci. Biotechnol. 2009, 3:1-8.
41. Psotova J., Chlopcikova S., Grambal F., Simanek V., Ulrichova J. Influence of silymarin and its flavonolignans on doxorubicin-iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother. Res. 2002, 16(Suppl 1):S63-S67.
42. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
43. Rho J.K., Choi Y.J., Jeon B.S., Choi S.J., Cheon G.J., Woo S.K., Kim H.R., Kim C.H., Choi C.M., Lee J.C. Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol. Cancer Ther. 2010, 9:3233-3243.
44. Scheel C., Weinberg R.A. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Semin. Cancer Biol. 2012, 22:396-403.
45. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
46. Singh R.P., Mallikarjuna G.U., Sharma G., Dhanalakshmi S., Tyagi A.K., Chan D.C., Agarwal C., Agarwal R. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance. Clin. Cancer Res. 2004, 10:8641-8647.
47. Singh R.P., Raina K., Sharma G., Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin. Cancer Res. 2008, 14:7773-7780.
48. Suda K., Tomizawa K., Fujii M., Murakami H., Osada H., Maehara Y., Yatabe Y., Sekido Y., Mitsudomi T. Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J. Thorac. Oncol. 2011, 6:1152-1161.
49. Tang X.Z., Hou S.X., He Y.J., Wang B.N. Preparation and in vitro evaluation of silymarin solid dispersions and complexation. West China J. Pham. Sci. 2001, 16:193-195.
50. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
51. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K.K., Gibson N., Haley J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65:9455-9462.
52. Wang K., Zhang H., Shen L., Du Q., Li J. Rapid separation and characterization of active flavonolignans of Silybum marianum by ultra-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J. Pharm. Biomed. Anal. 2010, 53:1053-1057.
53. Wu K., Zeng J., Li L., Fan J., Zhang D., Xue Y., Zhu G., Yang L., Wang X., He D. Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. Oncol. Rep. 2010, 23:1545-1552.
54. Xiao Y.Y., Song Y.M., Chen Z.P., Ping Q.N. Preparation of silymarin proliposomes and its pharmacokinetics in rats. Yao Xue Xue Bao 2005, 40:758-763.
55. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., Pham T.Q., Soriano R., Stinson J., Seshagiri S., Modrusan Z., Lin C.Y., O'Neill V., Amler L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005, 11:8686-8698.
56. Yu J.N., Xu X.M., Zhu Y., Gao H. Determination of concentration and encapsulation efficiency of silybin liposomes. Zhongguo Zhong Yao Za Zhi 2003, 28:1027-1030.
57. Zhang X., Liu G., Kang Y., Dong Z., Qian Q., Ma X. N-Cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell lines. PLoS One 2013, 8:e57692.
58. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X., Levine A.D., Rho J.K., Choi Y.J., Choi C.M., Kim S.W., Jang S.J., Park Y.S., Kim W.S., Lee D.H., Lee J.S., Miller V.A., Arcila M., Ladanyi M., Moonsamy P., Sawyers C., Boggon T.J., Ma P.C., Costa C., Taron M., Rosell R., Halmos B., Bivona T.G. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.
59. Zhao X.Y., Wang B.E., Wang T.L., Li X.M. Inhibitory effects of silymarin on hepatic fibrosis induced by dimethylnitrosamine: experiment with rats. Zhonghua Yi Xue Za Zhi 2006, 86:2563-2566.